A Study of Armored CAR T Cells in People With Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07783477
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Neuroendocrine Cancer
- Small Cell Lung Cancer
- Small Cell Lung Cancer ( SCLC )
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- DLL3-SAVVYZ-IL18 CAR T cell — DRUGDLL3-SAVVYZ-IL18 CAR T cell
Study Details
The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Key Dates
- First listed
- Aug 24, 2026
- Start date
- Sep 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Sep 30, 2029
- Completion
- Sep 30, 2029
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Level 1This is the starting dose of DLL3-SAVVYZ-IL18 CAR T cell Dose
- Experimental: Dose Level 2Eligible participants will receive DLL3-SAVVYZ-IL18 CAR T cell Dose at this Dose Level if no Dose Limiting Toxicities are experienced at Dose Level 1
- Experimental: Dose Level -1Eligible participants will receive DLL3-SAVVYZ-IL18 CAR T cell Dose at this Dose Level if Dose Limiting Toxicities are experienced at Dose Level 1
Primary Outcome Measure
Maximum Tolerated Dose/MTD of DLL3-SAVVYZ-IL18 CAR T cell [ Time Frame: up to 1 year ]
Central Contacts
- Adam Schoenfeld, MD646-608-4042
- Ritesh Kotecha, MD646-422-4791
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities) | Commack | New York | 11725 | |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | |
| Memorial Sloan Kettering Cancer Center (All protocol activities) | New York | New York | 10065 | |
| Memorial Sloan Kettering Cancer Center @ Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 |
Find similar trials in Basking Ridge, NJ
By condition
By specialty
By research site
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All protocol activities)· New York, NY
Related Studies
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · La Jolla, California
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)Recruiting · Tempus AI · Aurora, Colorado